Select Clinical Trials of RAS(ON) Inhibitors

At Revolution Medicines we are committed to the discovery, development, and delivery of targeted therapies for patients with RAS mutant cancer. Our RAS(ON) Inhibitor Clinical Trial Program is evaluating molecules aimed at targeting a broad range of RAS mutant cancers. Rat sarcoma (RAS) is a protein that is important in regulating cell division in our bodies. In certain cancers known as RAS mutant cancers, changes (or mutations) in the RAS gene cause the RAS protein to become mostly switched ON (or active), allowing the cancer cells to grow, spread, and survive

Investigational RAS(ON) inhibitors currently under development include:

• Daraxonrasib (RMC-6236), an oral, RAS(ON) multi-selective inhibitor that is selective for the active or "(ON)" state of multiple mutant forms of RAS (G12X, G13X, Q61X)
• Zoldonrasib (RMC-9805), an oral, RAS(ON) mutant-selective inhibitor that is selective for the active or "(ON)" state of RAS G12D
• Elironrasib (RMC-6291), an oral, RAS(ON) mutant-selective inhibitor that is selective for the active or "(ON)" state of RAS G12C
• RMC-5127, an oral, RAS(ON) mutant-selective inhibitor that is selective for the active or "(ON)" state of RAS G12V

RAS(ON) Inhibitor Clinical Trial Locator

RAS(ON) Inhibitor Clinical Trial Program

^aThis is not a complete list of eligibility criteria; for more information, please go to ClinicalTrials.gov. ^bTo view site-level status information, please go to ClinicalTrials.gov.

To potentially enroll in one of the above Revolution Medicines clinical trials, patients should discuss with their doctor whether they qualify for one of the above Revolution Medicines clinical trials.

These are select clinical trials only. To learn more about all our clinical trials, visit ClinicalTrials.gov.

*As of 08/26/2026, daraxonrasib has been approved only in the United States. Daraxonrasib is a prescription medicine used to treat adults with a type of pancreatic cancer called pancreatic adenocarcinoma:

- that has spread to other parts of the body, and

- who have received at least 1 prior treatment or who cannot receive a combination of cancer treatments.

The safety and efficacy of daraxonrasib has not been established by any other Regulatory Authority for this indication and for any other indication daraxonrasib remains investigational.
All other RAS(ON) inhibitors discussed are investigational and their safety and efficacy have not been established.

Reference

Daraxonrasib. Prescribing Information. Revolution Medicines, Inc.; 2026.